Plexium | A Comprehensive Drug Development Methodology
14869
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-14869,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
. DRUGDEVELOPMENTREIMAGINED
A Comprehensive Drug Development Methodology

ABOUT US

Plexium is a technology-first drug development company. We aim to improve efficiencies across the entire drug-development spectrum by leveraging techniques from various physical-science and computational disciplines.

 

In the near term we aim to enlarge the class of biological targets amenable to small-molecule modulation by recruiting the cells protein degradation machinery to targets of interest. Rather than use bi-functional molecules that link target-binders to E3 ligases, we develop ‘molecular glues’ that modify E3 ligase substrate-recognition. Our engineering background allows us to empirically search for molecular-glue degraders in massively high throughput cell-based assays utilizing DNA-encoded libraries.

Our long-terms interests are in studying biology and chemistry simultaneously, in relation and in response to each other, at extremely high throughputs, using multiplexed, unbiased assay readouts. We believe these tools have inherent diagnostic value, providing insights into both biomarkers and disease mechanisms, which are crucial to minimizing clinical attrition. We dream of a future where therapies can be personalized rapidly and inexpensively by screening against functional equivalents of individuals. We believe the tools we are developing will make this future a reality.

 

Please come join us if you can help bridge the rigor of drug development with the creative urgency to transform medicine. We are a highly interdisciplinary team, and welcome the opportunity to talk with you!

THERAPEUTIC FOCUS

We specialize in immunomodulation as a therapeutic approach for CNS and oncology.

LEADERSHIP

teams_0004_Team1

Swamy Vijayan

CEO, Serial Entrepreneur

Ex. Illumina, Omniome

JohnBoylanPhD

John Boylan

Chief Scientific Officer

Ex. Celgene, Roche, Amgen

teams_0003_Team2

Neil Raheja

VP Chemistry

Ex. Celgene, Pfizer

teams_0005_Team3

Mihai Azimiora

Director Chemistry

Ex. GNF, EJ Corey

teams_0000_Layer-1

Brian Paegel

Co-Founder, Advisor

Assoc. Professor TSRI

teams_0002_Team5

Manal Mehta

Finance, BD

Ex. Morgan Stanley

teams_0001_Team6

Pengyu Yang

Assays Cell Biology

Ex. CALIBR, Scripps

yi

Yi Zhang

Engineering

Ex. Omniome, Celula

INVESTORS

CONTACT US

Your Name (required)

Your Email (required)

Your Message

Address:

4202 Sorrento Valley Blvd, Suite A
San Diego, California 92121